MedPath

Ginkgo biloba

Generic Name
Ginkgo biloba
Drug Type
Biotech
CAS Number
90045-36-6
Unique Ingredient Identifier
19FUJ2C58T
Background

Ginkgo biloba extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of ginkgo biloba use the standardized extract of Ginkgo biloba (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in 1964. EGb761 contains 6% terpene lactones and 24% flavonoid glycosides. Flavonoids include quercetin, rutin, kaempferol, and isorhamnetin. Lactones include ginkgolide A, ginkgolide B, ginkgolide C, bilobalide, and ginkgotoxin, a lactone that is structurally related to pyridoxine. Ginkgo biloba is an herbal plant that is now cultivated worldwide. It is originally native to China, and ginkgo biloba extract has been used in traditional Chinese medicine for centuries.

After its nootropic properties were discovered, ginkgo biloba has gained attention as a therapeutic ingredient for memory and concentration enhancement in cognitive impairment and neurogenerative diseases, such as dementia. Ginkgo biloba was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders, and glaucoma. Ginkgo biloba is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA, and Health Canada. Ginkgo folium, the leaf extract of Ginkgo biloba, is considered an anti-dementia drug by the World Health Organization.

Indication

Ginkgo biloba does not currently have any approved therapeutic indications, and there is insufficient evidence to support its unapproved use. It is available in over-the-counter herbal products mostly for oral use, to improve memory and cognitive problems.

Associated Conditions
Cognitive Dysfunctions, Cognitive Functioning, Depression

Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa

Early Phase 1
Not yet recruiting
Conditions
Retinitis Pigmentosa
Interventions
Device: blue light-absorbing sunglasses
First Posted Date
2015-06-08
Last Posted Date
2015-06-08
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
404
Registration Number
NCT02465749
Locations
🇨🇳

State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

Role of Ginkgo Biloba Extract in IUGR

Phase 2
Completed
Conditions
Intrauterine Growth Restriction (IUGR)
Interventions
First Posted Date
2015-04-24
Last Posted Date
2016-03-22
Lead Sponsor
Assiut University
Target Recruit Count
226
Registration Number
NCT02425436

Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity

Early Phase 1
Completed
Conditions
Cognition
Blood Pressure
Interventions
First Posted Date
2015-03-12
Last Posted Date
2015-03-13
Lead Sponsor
Sunway University
Target Recruit Count
48
Registration Number
NCT02386852
Locations
🇲🇾

Department of Psychology, Sunway University, Bandar Sunway, Selangor, Malaysia

Ginkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma

Phase 2
Completed
Conditions
Glaucoma, Open-Angle
Interventions
Drug: Placebo to Ginkgo biloba
First Posted Date
2015-03-03
Last Posted Date
2015-03-03
Lead Sponsor
Maisonneuve-Rosemont Hospital
Target Recruit Count
19
Registration Number
NCT02376114
Locations
🇨🇦

Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

The Efficacy of Steroid Therapy in Vestibular Neuritis

Phase 3
Completed
Conditions
Vestibular Neuritis
Interventions
First Posted Date
2014-03-28
Last Posted Date
2019-01-10
Lead Sponsor
Asan Medical Center
Target Recruit Count
40
Registration Number
NCT02098330
Locations
🇰🇷

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy

Not Applicable
Withdrawn
Conditions
Tinnitus
Interventions
Behavioral: modified TRT
First Posted Date
2012-08-13
Last Posted Date
2016-10-25
Lead Sponsor
Seoul National University Hospital
Registration Number
NCT01663467
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders

Phase 3
Withdrawn
Conditions
Memory Deficit
Interventions
Drug: Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin
First Posted Date
2012-07-11
Last Posted Date
2021-02-24
Lead Sponsor
EMS
Registration Number
NCT01637168
Locations
🇧🇷

Cliníca Dr. Felício Savioli, Cotia, São Paulo, Brazil

Ginkgo Biloba Extract for Schizophrenia

Not Applicable
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2012-02-02
Last Posted Date
2016-07-12
Lead Sponsor
Beijing HuiLongGuan Hospital
Target Recruit Count
124
Registration Number
NCT01524380
Locations
🇨🇳

Beijing HuiLongGuan Hospital, Beijing, China

The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)

Phase 1
Completed
Conditions
Mild Cognitive Impairment
HIV Infections
Depression
Interventions
First Posted Date
2010-11-23
Last Posted Date
2020-11-30
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
18
Registration Number
NCT01246804
Locations
🇳🇱

CRCN, Radboud University Medical Centre, Nijmegen, Netherlands

The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans

Phase 2
Completed
Conditions
Ototoxicity
Hearing Loss
Interventions
First Posted Date
2010-06-08
Last Posted Date
2010-06-08
Lead Sponsor
University of Brasilia
Target Recruit Count
15
Registration Number
NCT01139281
Locations
🇧🇷

Hospital de Base do Distrito Federal (HBDF), Brasília, DF, Brazil

© Copyright 2025. All Rights Reserved by MedPath